SNPX Profile
Synaptogenix, Inc. is a biopharmaceutical company dedicated to advancing the treatment of neurodegenerative and cognitive disorders through innovative therapeutic approaches. The company's primary focus is on developing a drug platform centered around Bryostatin-1, a promising investigational compound for the treatment of Alzheimer’s disease. Bryostatin-1, derived from marine organisms, is being evaluated for its potential to enhance synaptic function and slow the progression of Alzheimer's, a disease characterized by cognitive decline and memory loss.
In addition to Alzheimer’s disease, Synaptogenix is exploring the therapeutic potential of Bryostatin-1 for a range of other neurodegenerative and cognitive conditions. These include fragile X syndrome, a genetic disorder associated with developmental disabilities; multiple sclerosis, an autoimmune disease affecting the central nervous system; and Niemann-Pick type C disease, a rare genetic disorder that leads to neurodegeneration. The company’s research aims to address these challenging diseases by leveraging Bryostatin-1’s mechanisms to potentially restore or improve cognitive function.
Synaptogenix has established strategic licensing agreements with prestigious institutions to advance its research and development efforts. These include collaborations with Stanford University, Icahn School of Medicine at Mount Sinai, and The Board of Trustees of the Leland Stanford Junior University. These partnerships provide Synaptogenix with access to cutting-edge research, resources, and expertise, which are essential for the successful development of its drug candidates.
Incorporated in 2012 and headquartered in New York, New York, Synaptogenix is at the forefront of biopharmaceutical innovation in the field of neurodegenerative diseases. The company’s commitment to addressing unmet medical needs through its proprietary drug platform underscores its role as a key player in the development of novel therapies for cognitive and neurological disorders.
|
